Evaluation of potential bacterial protease inhibitor properties of selected hydroxyquinoline derivatives : an in silico docking and molecular dynamics simulation approach
Riaz, Faiza and Hossain, Md. Sanower and Roney, Miah and Ali, Yousaf and Qureshi, Saira and Muhammad, Riaz and Abd Hamid, Shafida and Seidel, Veronique and ur Rashid, Haroon and Chiau Ming, Long (2023) Evaluation of potential bacterial protease inhibitor properties of selected hydroxyquinoline derivatives : an in silico docking and molecular dynamics simulation approach. Journal of Biomolecular Structure and Dynamics, 41 (19). pp. 9756-9769. ISSN 1538-0254 (https://doi.org/10.1080/07391102.2022.2146200)
Preview |
Text.
Filename: Riaz_etal_JBSD_2022_Evaluation_of_potential_bacterial_protease_inhibitor_properties_of_selected_hydroxyquinoline_derivatives.pdf
Accepted Author Manuscript License: Download (1MB)| Preview |
Abstract
Antimicrobial drug resistance (AMR) is a severe global threat to public health. The increasing emergence of drug-resistant bacteria requires the discovery of novel antibacterial agents. Quinoline derivatives have previously been reported to exhibit antimalarial, antiviral, antitumor, antiulcer, antioxidant and, most interestingly, antibacterial properties. In this study, we evaluated the binding affinity of three newly designed hydroxyquinolines derived from sulfanilamide (1), 4-amino benzoic acid (2) and sulfanilic acid (3) towards five bacterial protein targets (PDB ID: 1JIJ, 3VOB, 1ZI0, 6F86, 4CJN). The three derivatives were designed considering the amino acid residues identified at the active site of each protein involved in the binding of each co-crystallized ligand and drug-likeness properties. The ligands displayed binding energy values with the target proteins ranging from −2.17 to −8.45 kcal/mol. Compounds (1) and (3) showed the best binding scores towards 1ZI0/3VOB and 1JIJ/4CJN, respectively, which may serve as new antibiotic scaffolds. Our in silico results suggest that sulfanilamide (1) or sulfanilic acid (3) hydroxyquinoline derivatives have the potential to be developed as bacterial inhibitors, particularly MRSA inhibitors. But before that, it must go through the proper preclinical and clinical trials for further scientific validation. Further experimental studies are warranted to explore the antibacterial potential of these compounds through preclinical and clinical studies. Communicated by Ramaswamy H. Sarma.
ORCID iDs
Riaz, Faiza, Hossain, Md. Sanower, Roney, Miah, Ali, Yousaf, Qureshi, Saira, Muhammad, Riaz, Abd Hamid, Shafida, Seidel, Veronique ORCID: https://orcid.org/0000-0003-3880-5261, ur Rashid, Haroon and Chiau Ming, Long;-
-
Item type: Article ID code: 83502 Dates: DateEvent24 November 2023Published18 November 2022Published Online6 November 2022AcceptedSubjects: Medicine > Pharmacy and materia medica > Pharmaceutical chemistry
Science > MicrobiologyDepartment: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 13 Dec 2022 10:30 Last modified: 25 Sep 2024 17:23 URI: https://strathprints.strath.ac.uk/id/eprint/83502